| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| Morgan Stanley startet Gilead Sciences, Celgene und Biogen Idec mit Overweight. | | 97 | BörseGo |
| Morgan Stanley startet Gilead Sciences, Celgene und Biogen Idec mit Overweight.
(© BörseGo AG 2012 - Autor: Thomas Gansneder, Redakteur)
Mehr lesen zu:
Morgan Stanley startet Gilead Sciences, Celgene und Biogen Idec mit Overweight. | |
| 08.02.
| Biogen Idec to Present at the Leerink Swann Global Healthcare Conference | | 28 | Business Wire |
| Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at
the Leerink Swann Global Healthcare Conference will be webcast live on
Wednesday, February 15...
Mehr lesen zu:
Biogen Idec to Present at the Leerink Swann Global Healthcare Conference | |
| 08.02.
| Biogen Idec Crosses Below its 10-day MA | | 5 | SmarTrend |
| 08.02.
| Biogen gains recombinant factor VIII, factor IX manufacturing rights | | 4 | Pharma Bus Review |
| 07.02.
| BIOGEN IDEC - Sind das potenzielle Kaufkurse? | | 24 | GodmodeTrader.de |
| 07.02.
| Biogen Idec has the Highest Free Cash Flow Per Share in the Biotechnology Industry | | 3 | SmarTrend |
| 06.02.
| Swedish Orphan Biovitrum AB (publ): Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs | | 49 | Thomson Reuters ONE |
| Sobi and Biogen Idec have agreed to disclose further details on their agreement regarding development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs...
Mehr lesen zu:
Swedish Orphan Biovitrum AB (publ): Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs | |
| 03.02.
| 2012 Economic Outlook - Report Highlights VIVUS, Inc. and Biogen Idec Inc. | | 20 | MarketWire |
| HONG KONG -- (Marketwire) -- 02/03/12 -- Today, www.BrightonMarkets.com announced new reports highlighting VIVUS, Inc. (NASDAQ: VVUS) and Biogen Idec Inc. (NASDAQ: BIIB). Gain market insight with full...
Mehr lesen zu:
2012 Economic Outlook - Report Highlights VIVUS, Inc. and Biogen Idec Inc. | |
| 03.02.
| Highest Sales per Share in the Biotechnology Industry Detected in Shares of Biogen Idec | | 1 | SmarTrend |
| 02.02.
| Shares of Biogen Idec Rise Above Previous 52-Week High | | 1 | SmarTrend |
| 02.02.
| Equity Research on Amgen Inc. and Biogen Idec Inc. - Biotech Industry Growing | | 20 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 02/02/12 -- www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members...
Mehr lesen zu:
Equity Research on Amgen Inc. and Biogen Idec Inc. - Biotech Industry Growing | |
| 01.02.
| Watch for Continued Gains in Shares of Biogen Idec | | 3 | SmarTrend |
| 01.02.
| Biogen Idec Shares Up 23.2% Since SmarTrend's Buy Recommendation | | 2 | SmarTrend |
| 01.02.
| The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche | | 52 | PR Newswire |
| CHICAGO, Feb. 1, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche | |
| 31.01.
| EPS Beat for Biogen; Outlook Weak | | 8 | Zacks |
| 31.01.
| Biogen Idec Outruns Estimates Again | | 3 | Motley Fool |
| 31.01.
| Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript | | 2 | Seeking Alpha |
| 31.01.
| Biogen Idec: Am Allzeithoch | | 85 | Bernecker Börsenbriefe |
| Wird die Marke 118,72 Dollar vom 28. Oktober 2011 heute geschlagen? Dies ist - auf Basis von Tagesschlusskursen - das bisherige Allzeithoch. Das Biotechunternehmen Biogen Idec zeigt heute die Zahlen...
Mehr lesen zu:
Biogen Idec: Am Allzeithoch | |
| 31.01.
| TYSABRI Lifts Biogen (BIIB) to Q4 Beat; FY12 Outlook is Muted | | 4 | StreetInsider.com |
| 31.01.
| Biogen Idec profitiert von Blockbuster-Präparaten | | 72 | BörseGo |
| Cambridge (BoerseGo.de) - Das US-Biotechnologieunternehmen Biogen Idec hat im vierten Quartal einen Gewinnanstieg verzeichnet. Der Nettogewinn konnte im Berichtszeitraum Oktober bis Dezember 2011 auf...
Mehr lesen zu:
Biogen Idec profitiert von Blockbuster-Präparaten | |
